Gemcitabine, Tegafur-uracil, and Vinorelbine combination

This is a triplet chemotherapy regimen studied for the treatment of non-small cell lung cancer (NSCLC). A Phase II study evaluated its efficacy and toxicity in patients with stage IIIB or IV NSCLC. The regimen involved intravenous vinorelbine and gemcitabine on days 6 and 13, and oral tegafur-uracil (UFT) on days 1-5 and 8-12, repeated every three weeks. In the study with 32 patients, the objective response rate was 21.9%, median survival time was 13.9 months, and the one-year survival rate was 56.7%. Common toxicities included leukocytopenia (40.6%) and neutropenia (56.3%). Researchers concluded that while the regimen was well-tolerated with an acceptable toxicity profile, its response rate and median survival did not encourage further investigation.